---
title: "Biotech lawsuits and securities class actions, latest"
url: "https://aibio.space/legal/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "153 stories, updated every morning. Securities class actions, derivative suits, SEC matters and other litigation that affects shareholders of public biotech…"
---

# Legal

Securities class actions, derivative suits, SEC matters and other litigation that affects shareholders of public biotech companies, newest first.

All of it in one table: the [class action and lawsuit tracker](https://aibio.space/class-action-tracker/), with a CSV download.

Legal · 2026-10-29

## [Alnylam details Texas patent suit, two Cipla patent cases and a U.S. Attorney subpoena](https://aibio.space/news/alnylam-details-texas-patent-suit-two-cipla-patent-cases-u-s-attorney/)

Alnylam's 10-Q for the quarter ended September 30, 2026 says the University of Texas System's patent suit over Onpattro now sits in Massachusetts, with trial set for August 2027. Alnylam is the plaintiff in two patent suits against Cipla, and a U.S. Attorney's Office subpoena on pricing records is open.

ALNY

The Capitol dome seen from below. Photo: U.S. Department of Homeland Security (Source), CC0, via rawpixel

Legal

### [Viking and Ligand dispute VK2809 license termination in San Diego court](https://aibio.space/news/viking-ligand-dispute-vk2809-license-termination-san-diego-court/)

Ligand sued Viking on May 19, 2026 after purporting to end the TR-Beta license. Viking cross-sued Ligand and Metabasis. A hearing on Ligand's demurrer is set for February 26, 2027.

VKTX

LGND

2026-10-29

Legal

### [Viking's ITC trade secret ruling against Ascletis is on appeal at Federal Circuit](https://aibio.space/news/vikings-itc-trade-secret-ruling-against-ascletis-appeal-federal/)

The ITC affirmed sanctions against Ascletis Bioscience, Gannex, Ascletis Pharmaceuticals, Ascletis Pharma and Jinzi Jason Wu in May 2025. Both sides appealed, and argument is expected in Q4 2027.

VKTX

2026-10-29

Legal

### [Court rules for Teva and Apotex in Vanda's HETLIOZ patent suits](https://aibio.space/news/court-rules-teva-apotex-vandas-hetlioz-patent-suits/)

A Delaware federal court granted summary judgment of non-infringement for Teva and Apotex in September 2026. Vanda is weighing its options, and its 10-Q also reports a DOJ notice and new generic-drug suits.

VNDA

2026-10-29

Legal

### [Indivior discloses Suboxone dental injury MDL of about 22,098 plaintiffs; no bellwether before 2028](https://aibio.space/news/indivior-discloses-suboxone-dental-injury-mdl-about-22-098-plaintiffs/)

Indivior Pharmaceuticals, Inc. is the named defendant in the Northern District of Ohio MDL. Canadian class actions name subsidiaries, and a qui tam case names Indivior Inc.

INDV

2026-10-29

## More legal news

1. Legal · 2026-10-29 [European patent court rules Enanta patent invalid in Paxlovid suit against Pfizer](https://aibio.space/news/european-patent-court-rules-enanta-patent-invalid-paxlovid-suit/) The Unified Patent Court found the '265 Patent invalid on Pfizer's counterclaim and called Enanta's infringement action unfounded. [ENTA](https://aibio.space/companies/enanta-pharmaceuticals/)
2. Legal · 2026-10-28 [Skye Bioscience faces nimacimab securities class action and two derivative suits](https://aibio.space/news/skye-bioscience-faces-nimacimab-securities-class-action-two-derivative/) Stout v. Skye Bioscience alleges misleading statements about nimacimab from November 4, 2024 to October 3, 2025. Two derivative suits captioned against Dhillon are stayed, and consolidation was sought on August 11. [SKYE](https://aibio.space/companies/skye-bioscience/)
3. Legal · 2026-10-28 [Skye Bioscience faces October 2026 retrial of Cunning whistleblower suit](https://aibio.space/news/skye-bioscience-faces-october-2026-retrial-cunning-whistleblower-suit/) A jury found for former employee Wendy Cunning in 2023. The Ninth Circuit vacated the judgment in 2024. Skye now estimates the legal contingency at $5,417,250 and cites settlement talks. [SKYE](https://aibio.space/companies/skye-bioscience/)
4. Legal · 2026-10-28 [Amarin settles Hikma patent and antitrust cases over generic Vascepa](https://aibio.space/news/amarin-settles-hikma-patent-antitrust-cases-generic-vascepa/) The 10-Q says the patent claims and Hikma's antitrust claims are to be dismissed with prejudice under settlements agreed on Oct 13. It also lists antitrust complaints from Dr. Reddy's, Teva and Apotex in New Jersey. [AMRN](https://aibio.space/companies/amarin/)
5. Legal · 2026-10-28 [Replimune 10-Q lists two Massachusetts securities class actions and consolidated derivative suits](https://aibio.space/news/replimune-10-q-lists-two-massachusetts-securities-class-actions/) The first class action was filed shortly after the FDA's first RP1 complete response letter. A motion to dismiss it is due to be fully briefed in December; the SEC closed its probe in June without recommending action. [REPL](https://aibio.space/companies/replimune/)
6. Legal · 2026-10-27 [Beta Bionics discloses securities class action over iLet statements](https://aibio.space/news/beta-bionics-discloses-securities-class-action-ilet-statements/) A purported stockholder sued Beta Bionics and certain executive officers in a California federal court in September. The company says a loss is not currently probable nor estimable. [BBNX](https://aibio.space/companies/beta-bionics/)
7. Legal · 2026-10-23 [Integra LifeSciences details New Jersey class action and two derivative suits in 10-Q](https://aibio.space/news/integra-lifesciences-details-new-jersey-class-action-two-derivative/) The 2023 Pembroke Pines suit over FDA findings at the Boston plant is still being contested after a supplemental amended complaint. Two derivative suits are stayed behind it. [IART](https://aibio.space/companies/integra-lifesciences/)
8. Legal · 2026-10-22 [CSL faces shareholder class action over FY26 guidance and disclosure](https://aibio.space/news/csl-faces-shareholder-class-action-fy26-guidance-disclosure/) The suit, filed in the Supreme Court of Victoria, covers investors who bought CSL securities between February 2025 and May 2026. CSL denies liability and says it will defend the case. [CSL](https://aibio.space/companies/csl/)
9. Legal · 2026-10-22 [Medpace discloses plaintiff dropped Ohio securities class action over book-to-bill ratio](https://aibio.space/news/medpace-discloses-plaintiff-dropped-ohio-securities-class-action-book/) Defendants: Medpace Holdings, August J. Troendle, Jesse J. Geiger and Kevin M. Brady. Plaintiff filed a voluntary dismissal without prejudice on October 12, and a derivative suit was also dropped. [MEDP](https://aibio.space/companies/medpace/)
10. Legal · 2026-10-21 [SomaLogic stockholder suit heads to 2027 trial without Standard BioTools; Palamedrix claim settled](https://aibio.space/news/somalogic-stockholder-suit-heads-2027-trial-without-standard-biotools/) A Delaware suit naming Casdin Capital and SomaLogic directors is set for a March 2027 bench trial. SRS had claimed up to $17.5 million in Palamedrix milestones; that matter is resolved and the company paid Illumina $7.5 million on its indemnity. [LAB](https://aibio.space/companies/labiana-health/)
11. Legal · 2026-10-20 [Lifecore reports July hearing on securities class action settlement](https://aibio.space/news/lifecore-reports-july-hearing-securities-class-action-settlement/) Carew v. Lifecore Biomedical names the company and unnamed executive officers. The final approval hearing was held on July 28, 2026. A separate New York suit by 22NW Fund continues against the company. [LFCR](https://aibio.space/companies/lifecore-biomedical/)
12. Legal · 2026-10-20 [Fifth Circuit vacates class certification in Filana securities class action](https://aibio.space/news/fifth-circuit-vacates-class-certification-filana-securities-class/) The appeals court sent the Texas case back for new class certification proceedings. A $31.25 million settlement was filed in June, and Remi Barbier and Lindsay Burns, named in the 10-Q, are not parties to it. [FLNA](https://aibio.space/companies/filana-therapeutics/)
13. Legal · 2026-10-19 [Curanex discloses two New York class actions tied to its August 2025 IPO](https://aibio.space/news/curanex-discloses-two-new-york-class-actions-tied-august-2025-ipo/) Curanex Pharmaceuticals is a defendant, with underwriters Dominari Securities LLC, Pacific Century Securities, LLC and Revere Securities LLC, in two New York class actions over its August 2025 IPO. Both suits allege Securities Act violations in the offering documents. [CURX](https://aibio.space/companies/curanex-pharmaceuticals/)
14. Legal · 2026-10-19 [Collegium settles Grünenthal patent suit over Nucynta ER generic for $17,000,000](https://aibio.space/news/collegium-settles-grunenthal-patent-suit-nucynta-er-generic-17-000-000/) The drugmaker ends its Nucynta license and royalties with Grünenthal and gets certain patents assigned to it. Grünenthal has filed a motion to dismiss the New Jersey case. [COLL](https://aibio.space/companies/collegium-pharmaceutical/)
15. Legal · 2026-10-19 [Ultragenyx and Baylor settle Dojolvi patent litigation with Navinta, generic entry set for 2033](https://aibio.space/news/ultragenyx-baylor-settle-dojolvi-patent-litigation-navinta-generic/) The 8-K says the New Jersey case followed Navinta's generic application. Navinta gets a royalty-free license from January 1, 2033; suits against other filers continue. [RARE](https://aibio.space/companies/ultragenyx-pharmaceutical/)
16. Legal · 2026-10-15 [Supernus inherits Sage securities class action, derivative suits and SEC subpoena](https://aibio.space/news/supernus-inherits-sage-securities-class-action-derivative-suits-sec/) Supernus (Nasdaq: SUPN) took on Sage's New York class action naming Barry Greene and Kimi Iguchi, three derivative suits against sixteen unnamed insiders, and an SEC subpoena. Supernus faces two merger suits of its own. [SUPN](https://aibio.space/companies/supernus-pharmaceuticals/)
17. Legal · 2026-10-15 [Actinium securities class action dismissed with prejudice; plaintiffs file appeal](https://aibio.space/news/actinium-securities-class-action-dismissed-prejudice-plaintiffs-file/) The case names Actinium and executives Sandesh Seth, Avinash Desai, Madhuri Vusirikala and Sergio Giralt. Four derivative suits against directors and officers follow the same allegations. [ATNM](https://aibio.space/companies/actinium-pharmaceuticals-delaware/)
18. Legal · 2026-10-15 [Jasper Therapeutics faced Oct 15 hearing on motion to dismiss briquilimab class action](https://aibio.space/news/jasper-therapeutics-faced-oct-15-hearing-motion-dismiss-briquilimab/) Defendants: Jasper and unnamed current and former officers; derivative suits are captioned against Martell and others. A motion to dismiss was set for hearing October 15, and no ruling is reported. [JSPR](https://aibio.space/companies/jasper-therapeutics/)
19. Legal · 2026-10-14 [Liquidia settles all patent and trade secret litigation with United Therapeutics](https://aibio.space/news/liquidia-settles-all-patent-trade-secret-litigation-united/) The 8-K lists a net $175.0 million payment to UTC, a further $145.4 million in installments, and a YUTREPIA label change removing PH-ILD. Three parties are also paid to end the RareGen case, and one of them is a related party. [LQDA](https://aibio.space/companies/liquidia/)[UTHR](https://aibio.space/companies/united-therapeutics/)
20. Legal · 2026-10-14 [Xeris sues Torrent, Rising and others in New Jersey over generic Keveyis patent](https://aibio.space/news/xeris-sues-torrent-rising-others-new-jersey-generic-keveyis-patent/) Xeris Biopharma's subsidiary filed two patent infringement suits on October 13 after a new Keveyis patent was granted. The 8-K names seven defendants. [XERS](https://aibio.space/companies/xeris-biopharma/)
21. Legal · 2026-10-13 [Weird Science demands $10 million to end Delaware Chancery suit and other claims against Lunai](https://aibio.space/news/weird-science-demands-10-million-end-delaware-chancery-suit-other/) Lunai's 10-K says the Oct 7 demand covers all pending litigation. The Chancery case alleges breach of a 2018 investor rights agreement, and mediation has not been scheduled. [LNAI](https://aibio.space/companies/lunai-bioworks/)
22. Legal · 2026-10-09 [Lunai Bioworks cites its Delaware suit against Seven Points Capital in Nasdaq trading halt request](https://aibio.space/news/lunai-bioworks-cites-delaware-suit-against-seven-points-capital-nasdaq/) Lunai's 8-K asks Nasdaq to suspend trading, citing records from its Delaware suit. A later 8-K says trading will be suspended on October 30 unless the company asks for a hearing, and it does not plan to ask. [LNAI](https://aibio.space/companies/lunai-bioworks/)
23. Legal · 2026-10-07 [Envoy Medical ends Atlas SPAC redemption suit in Delaware with no payment](https://aibio.space/news/envoy-medical-ends-atlas-spac-redemption-suit-delaware-no-payment/) Atlas Merchant Capital agreed to dismiss its Chancery Court claims with prejudice, the hearing health company says. Two former executives were also named as defendants. [COCH](https://aibio.space/companies/envoy-medical/)
24. Legal · 2026-10-07 [Neogen discloses appeal of dismissed Michigan securities suit and two related cases](https://aibio.space/news/neogen-discloses-appeal-dismissed-michigan-securities-suit-two-related/) A federal court dismissed the Michigan class action with prejudice on August 10, 2026 and plaintiffs have appealed. A Minnesota Securities Act class action and a Michigan derivative suit remain pending. [NEOG](https://aibio.space/companies/neogen/)
25. Legal · 2026-10-06 [Inovio faces securities class action and five derivative suits over INO-3107 statements](https://aibio.space/news/inovio-faces-securities-class-action-five-derivative-suits-ino-3107/) Inovio, CEO Jacqueline Shea and CFO Peter Kies are defendants in a Pennsylvania class action. Shea, Kies and seven directors are named in derivative suits. A lead plaintiff was appointed July 27, 2026. [INO](https://aibio.space/companies/inovio-pharmaceuticals/)
26. Legal · 2026-10-02 [Tonix gets Paragraph IV patent notice from Dr. Reddy's on generic TONMYA application](https://aibio.space/news/tonix-gets-paragraph-iv-patent-notice-dr-reddys-generic-tonmya/) Dr. Reddy's told Tonix on October 1, 2026 that it filed an ANDA for a generic version of TONMYA 2.8 mg sublingual tablets and certified that four Orange Book patents are invalid, unenforceable or not infringed. No lawsuit has been filed, and Tonix says it intends to enforce its rights. [TNXP](https://aibio.space/companies/tonix-pharmaceuticals/)
27. Legal · 2026-10-02 [Lantheus discloses three stockholder suits over its Curium merger and 16 demand letters](https://aibio.space/news/lantheus-discloses-three-stockholder-suits-curium-merger-16-demand/) Defendants: Lantheus Holdings and unnamed Board members, per the 8-K. Two New York and one Massachusetts complaint allege proxy omissions; the company says they lack merit. [LNTH](https://aibio.space/companies/lantheus/)
28. Legal · 2026-09-28 [Unicycive discloses another securities class action over its OLC application](https://aibio.space/news/unicycive-discloses-another-securities-class-action-olc-application/) Unicycive disclosed in an 8-K dated September 28, 2026 that a second securities class action was filed on September 3, 2026 against the company and certain of its officers over its oxylanthanum carbonate application. An earlier class action and two derivative suits are pending in the same federal court. [UNCY](https://aibio.space/companies/unicycive-therapeutics/)
29. Legal · 2026-09-25 [Jury awards Nektar $90 million in Lilly contract case; securities class action pending](https://aibio.space/news/jury-awards-nektar-90-million-lilly-contract-case-securities-class/) A federal jury found that Eli Lilly breached the implied covenant of good faith in a rezpegaldesleukin license with Nektar and awarded $90 million, according to an 8-K filed September 25, 2026. Nektar is also a defendant in a securities class action, Schramke v. Nektar Therapeutics, filed in March 2026. [NKTR](https://aibio.space/companies/nektar-therapeutics/)
30. Legal · 2026-09-23 [Sarepta faces securities class action and five derivative suits over Elevidys disclosures](https://aibio.space/news/sarepta-faces-securities-class-action-five-derivative-suits-elevidys/) The class action names Sarepta, Douglas Ingram, Louise Rodino-Klapac and Ian Estepan. Derivative suits name eight directors. A $39.0 million patent settlement with REGENXBIO followed on September 23, 2026. [SRPT](https://aibio.space/companies/sarepta-therapeutics/)
31. Legal · 2026-09-22 [Aytu BioPharma's Adzenys patent suit against Granules heads to a January 2027 trial](https://aibio.space/news/aytu-biopharmas-adzenys-patent-suit-against-granules-heads-january/) Aytu (Nasdaq: AYTU) is the plaintiff against Granules Pharmaceuticals in Delaware, with trial moved to January 12, 2027. It is also a nominal plaintiff in a Section 16(b) suit against Armistice, now on appeal. [AYTU](https://aibio.space/companies/aytu-biopharma/)
32. Legal · 2026-09-21 [AnaptysBio awaits post-trial argument in Delaware suit against GSK and Tesaro](https://aibio.space/news/anaptysbio-awaits-post-trial-argument-delaware-suit-against-gsk-tesaro/) AnaptysBio sued TESARO, Inc. and GSK on Nov. 20, 2025 over the dostarlimab collaboration. Trial ended July 17, 2026, and post-trial argument is set for Oct. 20. Tesaro's claim that AnaptysBio breached its duties was dismissed April 24. [ANAB](https://aibio.space/companies/anaptysbio/)
33. Legal · 2026-09-17 [Aquestive faces securities class action and derivative suit over Anaphylm NDA statements](https://aibio.space/news/aquestive-faces-securities-class-action-derivative-suit-anaphylm-nda/) Modica v. Aquestive names the company and chief executive Daniel Barber in New Jersey federal court. A derivative suit, Wilson v. Brown, is stayed behind it. [AQST](https://aibio.space/companies/aquestive-therapeutics/)
34. Legal · 2026-09-15 [Beta Bionics discloses securities class action filed September 4, 2026 over iLet statements](https://aibio.space/news/beta-bionics-discloses-securities-class-action-filed-september-4-2026/) A purported stockholder sued Beta Bionics and certain executive officers in federal court in California, alleging misstatements about iLet. The company says it intends to defend and that any loss is not currently probable or estimable. [BBNX](https://aibio.space/companies/beta-bionics/)
35. Legal · 2026-09-14 [Cardiff Oncology settles onvansertib license lawsuit with Nerviano Medical Sciences](https://aibio.space/news/cardiff-oncology-settles-onvansertib-license-lawsuit-nerviano-medical/) Cardiff Oncology settled its lawsuit against Nerviano Medical Sciences, the licensor of its lead drug onvansertib, on September 14, 2026. The case is dismissed with prejudice and the license is amended. Nerviano was the only defendant in the suit. [CRDF](https://aibio.space/companies/cardiff-oncology/)
36. Legal · 2026-09-11 [Acadia derivative settlement gets preliminary approval as securities class action stays pending](https://aibio.space/news/acadia-derivative-settlement-gets-preliminary-approval-securities/) Nine individuals are named in the derivative suit: Baker, Biggar, Soland, Brege, Davis, Garofalo, Daly, Harrigan and Srdjan (Serge) Stankovic. The class action names Acadia and unnamed officers. [ACAD](https://aibio.space/companies/acadia-pharmaceuticals/)
37. Legal · 2026-09-04 [Nutriband says lawsuit over ended offering engagement remains in discovery](https://aibio.space/news/nutriband-says-lawsuit-ended-offering-engagement-remains-discovery/) Joseph Gunnar and Lucosky Brookman sued Nutriband, CEO Gareth Sheridan, President Serguei Melnik, Vitalie Botgros, TII Jet Services and Wolf Blitz in 2023 over a terminated offering engagement. Nutriband denies the claims and has counterclaimed. [NTRB](https://aibio.space/companies/nutriband/)
38. Legal · 2026-08-20 [Abbott agrees to settle Gill case and preterm formula NEC claims for approximately $670 million](https://aibio.space/news/abbott-agrees-settle-gill-case-preterm-formula-nec-claims/) Abbott Laboratories, a defendant in numerous NEC lawsuits, agreed to resolve the Gill case, where a jury awarded $495 million, and claims for about 2,000 other infants. About 1,700 lawsuits remain pending. [ABT](https://aibio.space/companies/abbott-laboratories/)
39. Legal · 2026-08-19 [Mereo BioPharma faces securities class action naming its CEO and chief scientific officer](https://aibio.space/news/mereo-biopharma-faces-securities-class-action-naming-ceo-chief/) Dodge v. Mereo Biopharma Group PLC (1:26-cv-988) was filed Feb. 4, 2026 in the Southern District of New York. The lead plaintiff filed an amended complaint on July 13, 2026. [MREO](https://aibio.space/companies/mereo-biopharma/)
40. Legal · 2026-08-18 [Outlook Therapeutics faces securities class action and stayed derivative suit over LYTENAVA BLA](https://aibio.space/news/outlook-therapeutics-faces-securities-class-action-stayed-derivative/) The New Jersey court dismissed the second amended complaint in part on Dec. 23, 2025, and plaintiffs refiled. Outlook and certain unnamed officers are defendants; a Delaware derivative suit is stayed. [OTLK](https://aibio.space/companies/outlook-therapeutics/)
41. Legal · 2026-08-14 [Exicure's class action and derivative suits end with court-approved settlements](https://aibio.space/news/exicures-class-action-derivative-suits-end-court-approved-settlements/) Exicure's securities class action and its shareholder derivative suits are over, according to a quarterly report filed August 14, 2026. The class action settled for $5.625 million, funded by insurers, and the derivative suits were dismissed in June 2026 after court approval. [XCUR](https://aibio.space/companies/exicure/)
42. Legal · 2026-08-14 [Neumora IPO class action over navacaprant disclosures awaits ruling on dismissal motion](https://aibio.space/news/neumora-ipo-class-action-navacaprant-disclosures-awaits-ruling/) A Securities Act suit in New York names Neumora, certain executive officers and certain underwriters. Defendants' reply on their motion to dismiss the second amended complaint is due August 24, 2026. [NMRA](https://aibio.space/companies/neumora-therapeutics/)
43. Legal · 2026-08-14 [GT Biopharma sued by four convertible note holders over undelivered conversion shares](https://aibio.space/news/gt-biopharma-sued-four-convertible-note-holders-undelivered-conversion/) GT Biopharma is the only defendant named in New York suits by Z-One, Silberfein, DiPietro and the Werthman Trust. Z-One's claims were dismissed and appealed. The other three are in settlement talks. [GTBP](https://aibio.space/companies/gt-biopharma/)
44. Legal · 2026-08-14 [Vistagen faces securities class action and two derivative suits over PALISADE-3 trial statements](https://aibio.space/news/vistagen-faces-securities-class-action-two-derivative-suits-palisade-3/) A Northern District of California class action names Vistagen, CEO Shawn Singh and COO Joshua Prince. Two derivative suits are stayed behind it, and a separate pro se case was dismissed with prejudice on August 12. [VTGN](https://aibio.space/companies/vistagen-therapeutics/)
45. Legal · 2026-08-14 [HCW Biologics faces December jury trial in Florida mechanics lien foreclosure case](https://aibio.space/news/hcw-biologics-faces-december-jury-trial-florida-mechanics-lien/) BE&K Building Group sued HCW Biologics, Cogent Bank and subcontractors in Broward County over unpaid renovation invoices. Fisk Electric's suit was consolidated, and Cogent Bank has demanded the liens be cleared. [HCWB](https://aibio.space/companies/hcw-biologics/)
46. Legal · 2026-08-14 [Scilex loses ZTlido patent appeal as Federal Circuit affirms non-infringement ruling for Aveva](https://aibio.space/news/scilex-loses-ztlido-patent-appeal-federal-circuit-affirms-non/) The Federal Circuit affirmed on Aug. 4, 2026 that Aveva's generic does not infringe Scilex's ZTlido patents. Defendants were Aveva Drug Delivery Systems, Apotex Corp. and Apotex, Inc. [SCLX](https://aibio.space/companies/scilex/)
47. Legal · 2026-08-14 [Scilex and Semnur named in Sorrento equity holders' suit, now stayed in a California federal court](https://aibio.space/news/scilex-semnur-named-sorrento-equity-holders-suit-now-stayed-california/) Mevi et al. v. Ji et al. names Scilex, Semnur and others not listed in the 10-Q. The court stayed the case on June 25, 2026; Scilex's filings do not identify the other defendants. [SCLX](https://aibio.space/companies/scilex/)
48. Legal · 2026-08-14 [Capricor discloses new securities class action and derivative suit as FDA date slips](https://aibio.space/news/capricor-discloses-new-securities-class-action-derivative-suit-fda/) Defendants: Capricor and unnamed officers in the new July 30 class action, and Capricor and CEO Linda Marbán in the 2025 one. The FDA also moved the deramiocel date to November 22, 2026. [CAPR](https://aibio.space/companies/capricor-therapeutics/)
49. Legal · 2026-08-13 [Cytokinetics sues Bristol-Myers Squibb and MyoKardia in Delaware patent suit over MYQORZO](https://aibio.space/news/cytokinetics-sues-bristol-myers-squibb-myokardia-delaware-patent-suit/) Cytokinetics (Nasdaq: CYTK) filed a complaint on August 13, 2026, seeking a declaratory judgment that it does not infringe U.S. Patent No. 12,616,697 and that the patent's claims are invalid. The defendants are Bristol-Myers Squibb and MyoKardia. [CYTK](https://aibio.space/companies/cytokinetics/)
50. Legal · 2026-08-13 [Kyntra Bio accrues $7.0 million for indemnity tied to SEC case against ex-CMO](https://aibio.space/news/kyntra-bio-accrues-7-0-million-indemnity-tied-sec-case-against-ex-cmo/) Kyntra Bio, formerly FibroGen, says it must advance legal costs for an SEC case against its former chief medical officer and may have to cover some costs and judgments. It had accrued about $7.0 million for those obligations at June 30, 2026, up from an amount it called not material three months earlier. [KYNB](https://aibio.space/companies/kyntra-bio/)
51. Legal · 2026-08-13 [Calidi faces suits from two former finance staff and an investor's securities fraud claim](https://aibio.space/news/calidi-faces-suits-two-former-finance-staff-investors-securities-fraud/) Calidi, director and ex-CEO Allan Camaisa and ex-officer Ms. Pizarro are defendants in San Diego employment suits. Investor Yian Zeng's federal case against Calidi had a summary judgment hearing set for Aug 24, 2026. [CLDI](https://aibio.space/companies/calidi-biotherapeutics/)
52. Legal · 2026-08-13 [CorMedix faces DefenCath securities class action as derivative settlement heads to a hearing](https://aibio.space/news/cormedix-faces-defencath-securities-class-action-derivative-settlement/) The class action names CorMedix and six officers, including Khoso Baluch. A settlement of derivative suits naming 12 individuals had a final approval hearing set for September 23, 2026. [CRMD](https://aibio.space/companies/cormedix/)
53. Legal · 2026-08-13 [Alumis carries ACELYRIN securities class action over izokibep trial; dismissal motion pending](https://aibio.space/news/alumis-carries-acelyrin-securities-class-action-izokibep-trial/) Alumis (Nasdaq: ALMS) inherited Boukadoum v. Acelyrin in its May 2025 merger. The filing names ACELYRIN and unnamed officers and directors; ACELYRIN's 2024 signers are listed. [ALMS](https://aibio.space/companies/alumis/)
54. Legal · 2026-08-13 [ARS Pharmaceuticals details Aptar trade secret suit and its own antitrust claim over neffy parts](https://aibio.space/news/ars-pharmaceuticals-details-aptar-trade-secret-suit-own-antitrust/) AptarGroup and Aptar France sued ARS Pharmaceuticals and ARS Pharmaceuticals Operations in March 2025. The company's separate antitrust suit against AptarGroup was moved to New York in July 2026. [SPRY](https://aibio.space/companies/ars-pharmaceuticals/)
55. Legal · 2026-08-13 [ARS Pharmaceuticals faces securities class action over neffy insurance coverage timeline](https://aibio.space/news/ars-pharmaceuticals-faces-securities-class-action-neffy-insurance/) A stockholder sued the company and unnamed current and former officers in the Southern District of California on August 5, 2026. A pharmacy filed a separate fax-advertising class action in July. [SPRY](https://aibio.space/companies/ars-pharmaceuticals/)
56. Legal · 2026-08-13 [Fate Therapeutics faces securities class action and three derivative suits over Janssen disclosures](https://aibio.space/news/fate-therapeutics-faces-securities-class-action-three-derivative-suits/) The 10-Q says Fate and unnamed officers are defendants in a Southern District of California class action. The derivative suits are captioned against Wolchko; board lists come from Fate's 2023 and 2026 proxies. [FATE](https://aibio.space/companies/fate-therapeutics/)
57. Legal · 2026-08-13 [BioVie securities class certified in Nevada; three derivative suits stayed](https://aibio.space/news/biovie-securities-class-certified-nevada-three-derivative-suits-stayed/) The 10-K says the court certified the class on June 18, 2026 in In re BioVie Inc. Securities Litigation. BioVie and unnamed officers are defendants; insurance carries a $2 million deductible. [BIVI](https://aibio.space/companies/biovie/)
58. Legal · 2026-08-13 [Gossamer Bio faces securities class action; lead plaintiff named, amended complaint due Aug. 10](https://aibio.space/news/gossamer-bio-faces-securities-class-action-lead-plaintiff-named/) Kinnamon v. Gossamer Bio names the company and unnamed executive officers and directors over a June 16, 2025 to February 20, 2026 class period. The 10-Q gives no loss estimate. [GOSS](https://aibio.space/companies/gossamer-bio/)
59. Legal · 2026-08-12 [Alto Neuroscience IPO securities class action dismissed with leave to amend](https://aibio.space/news/alto-neuroscience-ipo-securities-class-action-dismissed-leave-amend/) A federal court in California dismissed the securities class action over Alto Neuroscience's ALTO-100 disclosures on August 7, 2026, and gave the plaintiffs leave to file a third amended complaint. A related derivative action has been stayed. [ANRO](https://aibio.space/companies/alto-neuroscience/)
60. Legal · 2026-08-12 [Inovio's supply-contract suit against VGXI and GeneOne is set for trial in October 2026](https://aibio.space/news/inovios-supply-contract-suit-against-vgxi-geneone-set-trial-october/) Inovio sued VGXI, Inc. and GeneOne Life Science, Inc. in a Pennsylvania state court in 2020 over a supply agreement. The defendants counterclaimed. A seven-day trial was scheduled to begin October 13, 2026. [INO](https://aibio.space/companies/inovio-pharmaceuticals/)
61. Legal · 2026-08-12 [Spero says SEC closed its investigation without action against it; two ex-executives settled](https://aibio.space/news/spero-says-sec-closed-investigation-without-action-against-two-ex/) The SEC fined former CEO Ankit Mahadevia $112,500 and former CFO Satyavrat Shukla $75,000 in a settled January 2026 order. Spero's letter of Jan 20, 2026 says the SEC does not intend to recommend action against it. [SPRO](https://aibio.space/companies/spero-therapeutics/)
62. Legal · 2026-08-12 [Humacyte securities suit over Symvess safety enters discovery; four derivative suits pending](https://aibio.space/news/humacyte-securities-suit-symvess-safety-enters-discovery-four/) The North Carolina class action names Humacyte and certain officers. Derivative suits name current or former directors and officers, and Ayabudge LLC in two cases. Product safety claims survived dismissal. [HUMA](https://aibio.space/companies/humacyte/)
63. Legal · 2026-08-12 [Atara Biotherapeutics faces securities class action over tab-cel ALLELE study statements](https://aibio.space/news/atara-biotherapeutics-faces-securities-class-action-tab-cel-allele/) Kuang v. Atara, filed in Central District of California, names the company and unnamed current and former officers. An amended complaint came on August 10, and defendants must respond by October 9. [ATRA](https://aibio.space/companies/atara-biotherapeutics/)
64. Legal · 2026-08-11 [Kyverna faces IPO securities class action and consolidated derivative suit](https://aibio.space/news/kyverna-faces-ipo-securities-class-action-consolidated-derivative-suit/) Kyverna Therapeutics is defending a Securities Act class action over its February 2024 IPO, which names the company, certain officers and directors, and the underwriters. A second amended complaint is under a motion to dismiss, with a hearing set for September 3, 2026. Two derivative suits filed in May 2025 were later consolidated. [KYTX](https://aibio.space/companies/kyverna-therapeutics/)
65. Legal · 2026-08-11 [Taysha derivative suit over 2023 private placement faces termination motion](https://aibio.space/news/taysha-derivative-suit-2023-private-placement-faces-termination-motion/) Stockholders sued in Delaware Chancery over the August 2023 private placement. A special litigation committee moved on March 3, 2026 to end the case, and the lead plaintiff does not oppose. [TSHA](https://aibio.space/companies/taysha-gene-therapies/)
66. Legal · 2026-08-11 [TherapeuticsMD's Mayne Pharma suit is stayed; IMVEXXY patent cases against Teva and Sun continue](https://aibio.space/news/therapeuticsmds-mayne-pharma-suit-stayed-imvexxy-patent-cases-against/) TherapeuticsMD (Nasdaq: TXMD) sued Mayne Pharma LLC in Delaware over net working capital allowances and faces a countersuit. Teva and Sun Pharma are defendants in New Jersey patent cases over generic IMVEXXY. [TXMD](https://aibio.space/companies/therapeuticsmd/)
67. Legal · 2026-08-11 [Erasca faces securities class action and ERAS-0015 derivative suit](https://aibio.space/news/erasca-faces-securities-class-action-eras-0015-derivative-suit/) Erasca (Nasdaq: ERAS) is named in a June class action in San Diego federal court. An August derivative suit names its current directors and CFO. The 10-Q names no officers in the class action. [ERAS](https://aibio.space/companies/erasca/)
68. Legal · 2026-08-11 [Bicara and Biocon face Y-Trap inventorship suit over ficerafusp alfa patents](https://aibio.space/news/bicara-biocon-face-y-trap-inventorship-suit-ficerafusp-alfa-patents/) Y-Trap, Inc. sued Bicara Therapeutics and Biocon Ltd in Massachusetts federal court in October 2024. Discovery is ongoing, and a patent office review Bicara requested was instituted on July 15, 2026. [BCAX](https://aibio.space/companies/bicara-therapeutics/)
69. Legal · 2026-08-11 [Gain Therapeutics and CEO Gene Mack sued in Delaware over warrant exercise price](https://aibio.space/news/gain-therapeutics-ceo-gene-mack-sued-delaware-warrant-exercise-price/) Warrant holder Andrew Schwartzberg seeks more than $3.1 million from Gain and Gene Mack for breach of contract, fraudulent inducement and promissory estoppel. Gain's 10-Q reports going concern doubt. [GANX](https://aibio.space/companies/gain-therapeutics/)
70. Legal · 2026-08-10 [Veru faces securities class action and five derivative suits over sabizabulin statements](https://aibio.space/news/veru-faces-securities-class-action-five-derivative-suits-sabizabulin/) Veru, Chairman and CEO Mitchell Steiner and CFO Michele Greco are defendants in a Florida class action. Five derivative suits name seven officers and directors. Veru says it cannot estimate losses. [VERU](https://aibio.space/companies/veru/)
71. Legal · 2026-08-10 [Veru faces fraud and warranty suit from the buyer of its FC2 business](https://aibio.space/news/veru-faces-fraud-warranty-suit-buyer-fc2-business/) Clear Future, Inc. sued Veru Inc. in Delaware Superior Court after buying the FC2 female condom business for $18.0 million in cash. Veru is the defendant named in the 10-Q and says it cannot estimate losses. [VERU](https://aibio.space/companies/veru/)
72. Legal · 2026-08-10 [Sana Biotechnology securities class action is stayed after second amended complaint](https://aibio.space/news/sana-biotechnology-securities-class-action-stayed-after-second-amended/) The Washington federal suit names Sana (Nasdaq: SANA), CEO Steven D. Harr and former CFO Nathan Hardy over SC291 statements. A second amended complaint was filed May 26, 2026, and the case is stayed. [SANA](https://aibio.space/companies/sana-biotechnology/)
73. Legal · 2026-08-10 [Rocket Pharmaceuticals faces securities class action and derivative suit over Danon trial](https://aibio.space/news/rocket-pharmaceuticals-faces-securities-class-action-derivative-suit/) Ho and Yankov complaints named Rocket, CEO Gaurav Shah and former CFO Aaron Ondrey. Rocket's motion to dismiss the consolidated complaint is pending, and a derivative suit is stayed. [RCKT](https://aibio.space/companies/rocket-pharmaceuticals/)
74. Legal · 2026-08-10 [Metagenomi's IPO class action over Moderna collaboration disclosures moves into discovery](https://aibio.space/news/metagenomis-ipo-class-action-moderna-collaboration-disclosures-moves/) Vreeland v. Metagenomi names the company, unnamed officers and directors under Section 11. The court partly denied dismissal on March 24, 2026; the S-1 shows who signed. [MGX](https://aibio.space/companies/metagenomi-therapeutics/)
75. Legal · 2026-08-10 [Axsome derivative suit dismissed in Delaware; New York case awaits ruling on motion](https://aibio.space/news/axsome-derivative-suit-dismissed-delaware-new-york-case-awaits-ruling/) Stockholders sued Axsome's directors and officers in New York and Delaware over AXS-07 statements. Delaware dismissed with prejudice on July 9, 2026. The New York motion to dismiss is fully briefed. [AXSM](https://aibio.space/companies/axsome-therapeutics/)
76. Legal · 2026-08-10 [Axsome resolves all Sunosi patent suits; Symbravo case against Apotex continues](https://aibio.space/news/axsome-resolves-all-sunosi-patent-suits-symbravo-case-against-apotex/) Axsome's 10-Q says it has settled with every current Sunosi ANDA filer, the last being Aurobindo on June 2, 2026. Its Symbravo patent suit against Apotex Inc. is in fact discovery. [AXSM](https://aibio.space/companies/axsome-therapeutics/)
77. Legal · 2026-08-10 [MoonLake faces securities class action over sonelokimab; motion to dismiss pending](https://aibio.space/news/moonlake-faces-securities-class-action-sonelokimab-motion-dismiss/) The Peters suit names MoonLake and its chief executive, chief financial and chief scientific officers. The class period runs March 10, 2024 through September 29, 2025. [MLTX](https://aibio.space/companies/moonlake-immunotherapeutics/)
78. Legal · 2026-08-07 [CervoMed discloses ex-CEO's 2014 suit, narrowed in March, with trial set for October](https://aibio.space/news/cervomed-discloses-ex-ceos-2014-suit-narrowed-march-trial-set-october/) Paul Feller sued RestorGenex, Pro Sports & Entertainment, ProElite and Stratus Media Group, GmbH in Los Angeles. The court dismissed some claims on March 26, 2026. CervoMed says it is defending itself vigorously. [CRVO](https://aibio.space/companies/cervomed/)
79. Legal · 2026-08-07 [Natera appeals Guardant false advertising judgment after $292.5 million verdict](https://aibio.space/news/natera-appeals-guardant-false-advertising-judgment-after-292-5-million/) A jury found Natera liable in November 2024 in the Northern District of California. Final judgment came in June 2026 and Natera is appealing to the Ninth Circuit. [NTRA](https://aibio.space/companies/natera/)
80. Legal · 2026-08-07 [Agenus securities class action dismissed, plaintiff appeals; SEC closes investigation](https://aibio.space/news/agenus-securities-class-action-dismissed-plaintiff-appeals-sec-closes/) The District of Massachusetts dismissed In re Agenus Inc. Securities Litigation on March 24, 2026. The lead plaintiff appealed to the First Circuit, where briefing began in June. Derivative suits remain stayed. [AGEN](https://aibio.space/companies/agenus/)
81. Legal · 2026-08-07 [ANI loses post-trial motions in CG Oncology royalty case and defends Acella suit](https://aibio.space/news/ani-loses-post-trial-motions-cg-oncology-royalty-case-defends-acella/) A Delaware court denied ANI's bid for a new trial against CG Oncology on July 16, and ANI plans to appeal. In Minnesota, ANI is defending Acella's Lanham Act suit, with summary judgment argument set for August 25. [ANIP](https://aibio.space/companies/ani-pharmaceuticals/)[CGON](https://aibio.space/companies/cg-oncology/)
82. Legal · 2026-08-07 [ANI and Novitium face two generic drug patent suits and antitrust counterclaims in a third](https://aibio.space/news/ani-novitium-face-two-generic-drug-patent-suits-antitrust/) Orphalan sued Novitium, and Xeris and Strongbridge sued Novitium and ANI. In a Harmony patent case against AET and Sandoz entities, the defendants counterclaim against Harmony and Novitium. [ANIP](https://aibio.space/companies/ani-pharmaceuticals/)
83. Legal · 2026-08-07 [Merck faces securities class action over Gardasil demand in China, with derivative suits stayed](https://aibio.space/news/merck-faces-securities-class-action-gardasil-demand-china-derivative/) Cronin v. Merck in New Jersey names Merck and unnamed officers. The 10-Q gives no individual defendants; Merck's filings show its CEO, CFO and 13 director nominees. [MRK](https://aibio.space/companies/merck-mrk-xetr/)
84. Legal · 2026-08-07 [aTyr Pharma moves to dismiss amended class action over efzofitimod statements](https://aibio.space/news/atyr-pharma-moves-dismiss-amended-class-action-efzofitimod-statements/) Defendants: aTyr Pharma, CEO Sanjay Shukla and, since May, CFO Jill M. Broadfoot. The July 17 motion to dismiss targets the amended complaint; aTyr committed on August 7 to cut 60% of staff. [ATYR](https://aibio.space/companies/atyr-pharma/)
85. Legal · 2026-08-06 [Ardelyx securities suit over Xphozah ends after appeal is withdrawn](https://aibio.space/news/ardelyx-securities-suit-xphozah-ends-after-appeal-withdrawn/) Yarborough v. Ardelyx named the company and executives Michael Raab, Susan Rodriguez, Laura Williams and Elizabeth Grammer. The First Circuit appeal was dismissed on March 26, 2026. [ARDX](https://aibio.space/companies/ardelyx/)
86. Legal · 2026-08-06 [Gilead HIV antitrust appeal awaits ruling after October 2025 argument; Aetna trial set for 2027](https://aibio.space/news/gilead-hiv-antitrust-appeal-awaits-ruling-after-october-2025-argument/) Gilead, Bristol-Myers Squibb, Johnson & Johnson and Teva are defendants in consolidated federal suits over HIV drugs. Gilead paid $525 million in 2023 to settle with the direct purchaser class and retailer opt-out plaintiffs. [GILD](https://aibio.space/companies/gilead-sciences/)
87. Legal · 2026-08-06 [Gilead cites August 2026 ruling in HIV drug injury suits with about 23,000 active plaintiffs](https://aibio.space/news/gilead-cites-august-2026-ruling-hiv-drug-injury-suits-about-23-000/) The 10-Q names Gilead as defendant, with no co-defendants listed, in a putative class action and product liability suits over Viread, Truvada, Atripla, Complera and Stribild. A federal bellwether trial is set for March 2027. [GILD](https://aibio.space/companies/gilead-sciences/)
88. Legal · 2026-08-06 [Iovance faces securities class action and three derivative suits over 2025 revenue forecast](https://aibio.space/news/iovance-faces-securities-class-action-three-derivative-suits-2025/) Iovance (Nasdaq: IOVA) and unnamed officers are defendants in a California class action over 2025 revenue guidance. Derivative suits against Frederick Vogt, Jean-Marc Bellemin and others are stayed. Iovance has moved to dismiss. [IOVA](https://aibio.space/companies/iovance-biotherapeutics/)
89. Legal · 2026-08-06 [Iovance defends two Delaware derivative suits over director pay and a 2024 stock offering](https://aibio.space/news/iovance-defends-two-delaware-derivative-suits-director-pay-2024-stock/) Iovance (Nasdaq: IOVA) is a nominal defendant in two Court of Chancery suits against its directors. A 2020 pay suit is consolidated and a 2024 offering suit is in motion-to-dismiss briefing. [IOVA](https://aibio.space/companies/iovance-biotherapeutics/)
90. Legal · 2026-08-06 [Intellia says court dismissed securities class action; director pay and patent suits continue](https://aibio.space/news/intellia-says-court-dismissed-securities-class-action-director-pay/) A Massachusetts court fully granted dismissal of the Gonzalez suit against Intellia (Nasdaq: NTLA) and unnamed officers on June 18, 2026. A Delaware suit against directors and BlueAllele's patent suit remain open. [NTLA](https://aibio.space/companies/intellia-therapeutics/)
91. Legal · 2026-08-06 [Viatris faces Indore plant securities class action and derivative suits in two federal courts](https://aibio.space/news/viatris-faces-indore-plant-securities-class-action-derivative-suits/) Viatris (Nasdaq: VTRS) and unnamed current and former officers are defendants in a Pennsylvania class action over Indore disclosures. Derivative suits name officers and directors in Pennsylvania and Delaware. [VTRS](https://aibio.space/companies/viatris/)
92. Legal · 2026-08-06 [Relay Therapeutics is nominal defendant in Delaware derivative suit over 2021 to 2023 board pay](https://aibio.space/news/relay-therapeutics-nominal-defendant-delaware-derivative-suit-2021/) Hayes v. Borisy, filed December 2024, names Borisy and other directors and officers of Relay (Nasdaq: RLAY) that the 10-Q does not list. The case is in discovery and Relay cannot predict the outcome or any loss. [RLAY](https://aibio.space/companies/relay-therapeutics/)
93. Legal · 2026-08-06 [Federal Circuit affirms invalidity of Puma-licensed patents in Tagrisso suit against AstraZeneca](https://aibio.space/news/federal-circuit-affirms-invalidity-puma-licensed-patents-tagrisso-suit/) The Federal Circuit affirmed on July 9, 2026 that the asserted patent claims are invalid. Wyeth, the Pfizer subsidiary and co-plaintiff, had won a $107.5 million jury award against AstraZeneca Pharmaceuticals LP and AstraZeneca AB. [PBYI](https://aibio.space/companies/puma-biotechnology/)
94. Legal · 2026-08-06 [Puma's malpractice suit against former law firm waits on North Carolina Supreme Court](https://aibio.space/news/pumas-malpractice-suit-against-former-law-firm-waits-north-carolina/) Puma is suing Hedrick Gardner Kincheloe & Garofalo, L.L.P. and attorney David L. Levy over its defense in the Eshelman case. The Court of Appeals revived the claim on Sept. 3, 2025. [PBYI](https://aibio.space/companies/puma-biotechnology/)
95. Legal · 2026-08-06 [Ocugen awaits Third Circuit ruling in dismissed securities suit as derivative suits remain stayed](https://aibio.space/news/ocugen-awaits-third-circuit-ruling-dismissed-securities-suit/) The 10-Q says the defendants in the Pennsylvania class action are the company and "certain of its agents" and names none. Derivative suits in two courts are stayed, and a Delaware class action over the charter was dismissed as moot. [OCGN](https://aibio.space/companies/ocugen/)
96. Legal · 2026-08-06 [Arcturus sues AbbVie and Capstan over trade secrets, and Capstan counterclaims](https://aibio.space/news/arcturus-sues-abbvie-capstan-trade-secrets-capstan-counterclaims/) Arcturus filed in the Southern District of California on September 23, 2025. Capstan Therapeutics answered with counterclaims against the company and two employees, and no trial date is set. [ARCT](https://aibio.space/companies/arcturus-therapeutics/)
97. Legal · 2026-08-06 [PepGen reports its securities class action and shareholder demand are over](https://aibio.space/news/pepgen-reports-securities-class-action-shareholder-demand/) The 10-Q says the Karam suit against PepGen, its CEO and its CFO was voluntarily dismissed on Nov. 18, 2025. The filing does not name the officers; the 2023 annual report shows McArthur and Donnelly. [PEPG](https://aibio.space/companies/pepgen/)
98. Legal · 2026-08-06 [Verrica agrees in principle to settle 2022 securities class action over YCANTH](https://aibio.space/news/verrica-agrees-principle-settle-2022-securities-class-action-ycanth/) Defendants: Verrica and unnamed current and former officers and directors. A July term sheet would end a case certified in March; Verrica accrued $4.0 million and needs court approval. [VRCA](https://aibio.space/companies/verrica-pharmaceuticals/)
99. Legal · 2026-08-05 [Perrigo faces New York securities class action over infant formula statements](https://aibio.space/news/perrigo-faces-new-york-securities-class-action-infant-formula/) The 10-Q names Perrigo, CFO Eduardo Bezerra and former CEOs Patrick Lockwood-Taylor and Murray Kessler in French v. Perrigo. A Teamsters pension fund is lead plaintiff and filed an amended complaint on May 1, 2026. [PRGO](https://aibio.space/companies/perrigo/)
100. Legal · 2026-08-05 [BioAge faces Ninth Circuit appeal of dismissed IPO securities class action](https://aibio.space/news/bioage-faces-ninth-circuit-appeal-dismissed-ipo-securities-class/) BioAge Labs' 10-Q says a federal court dismissed the IPO securities class action with prejudice on March 2, 2026, and the plaintiff has appealed to the Ninth Circuit. The defendants are BioAge, its directors and certain officers, and the filings do not name the officers. [BIOA](https://aibio.space/companies/bioage-labs/)
101. Legal · 2026-08-05 [Geron faces Rytelo securities class action and four derivative suits](https://aibio.space/news/geron-faces-rytelo-securities-class-action-four-derivative-suits/) Geron is a defendant in a consolidated securities class action over statements about RYTELO, and four derivative suits repeat the claims. The class action was dismissed without prejudice on March 30, 2026, and a second amended complaint is now under a motion to dismiss. [GERN](https://aibio.space/companies/geron/)
102. Legal · 2026-08-05 [Revolution Medicines reports final judgment in Delaware suit over EQRx merger](https://aibio.space/news/revolution-medicines-reports-final-judgment-delaware-suit-eqrx-merger/) The Court of Chancery dismissed Nemeth v. Casdin with prejudice on June 18, 2026 after a settlement. Revolution was named only as successor to EQRx, alongside its director Alexis Borisy and others. [RVMD](https://aibio.space/companies/revolution-medicines/)
103. Legal · 2026-08-05 [Context Therapeutics closes Delaware suit over three-year director terms; $850,000 fee paid](https://aibio.space/news/context-therapeutics-closes-delaware-suit-three-year-director-terms/) The Vladimir Gusinsky Revocable Trust sued Context and its directors on February 4, 2026. A consent judgment voided two charter provisions, and a third party paid plaintiff's counsel $850,000. [CNTX](https://aibio.space/companies/context-therapeutics/)
104. Legal · 2026-08-05 [Amgen agrees to settle Roofers securities class action over IRS tax disclosures](https://aibio.space/news/amgen-agrees-settle-roofers-securities-class-action-irs-tax/) Amgen, CEO Robert Bradway and CFO Peter Griffith agreed to settle the New York class action, subject to court approval. Derivative suits against directors are stayed. [AMGN](https://aibio.space/companies/amgen/)
105. Legal · 2026-08-05 [Amgen's ChemoCentryx securities class action settlement gets preliminary approval](https://aibio.space/news/amgens-chemocentryx-securities-class-action-settlement-gets/) Homyk v. ChemoCentryx named ChemoCentryx and its CEO over TAVNEOS statements. A California federal court preliminarily approved a class settlement on June 12, 2026; final hearing is October 29. [AMGN](https://aibio.space/companies/amgen/)
106. Legal · 2026-08-05 [BioCryst sues Annora, Hetero and Camber in Delaware over generic ORLADEYO](https://aibio.space/news/biocryst-sues-annora-hetero-camber-delaware-generic-orladeyo/) BioCryst filed the patent suit on March 10, 2025 after Paragraph IV notices from Annora Pharma. The 10-Q says the case is in early stages and no estimate of loss is possible. [BCRX](https://aibio.space/companies/biocryst-pharmaceuticals/)
107. Legal · 2026-08-05 [Recursion and its lab landlord remain in Utah court over lease construction claims](https://aibio.space/news/recursion-lab-landlord-remain-utah-court-lease-construction-claims/) Industry Office SLC sued Recursion in 2023 for breach of contract; Recursion counterclaimed for breach and fraudulent misrepresentation. Both sides are in discovery. An Exscientia class action ended in December 2025. [RXRX](https://aibio.space/companies/recursion-pharmaceuticals/)
108. Legal · 2026-08-05 [Acadia awaits Federal Circuit ruling in Nuplazid patent suits; Zydus trial set for Nov. 2](https://aibio.space/news/acadia-awaits-federal-circuit-ruling-nuplazid-patent-suits-zydus-trial/) Acadia is the plaintiff against Aurobindo, MSN, Teva and Zydus entities. A June 2025 judgment for Acadia is on appeal, and a new Zydus case goes to trial November 2, 2026. [ACAD](https://aibio.space/companies/acadia-pharmaceuticals/)
109. Legal · 2026-08-05 [Mirum sues Sandoz, Hetero, Biophore and Zydus in Delaware over generic Livmarli; trial set for 2028](https://aibio.space/news/mirum-sues-sandoz-hetero-biophore-zydus-delaware-generic-livmarli/) Mirum, Satiogen and Shire Human Genetic Therapies are plaintiffs in four consolidated cases. A 30-month FDA stay runs through March 29, 2029, and the Markman hearing is April 21, 2027. [MIRM](https://aibio.space/companies/mirum-pharmaceuticals/)
110. Legal · 2026-08-04 [Niagen Bioscience details consumer class actions, Thorne suit and Elysium fee appeal](https://aibio.space/news/niagen-bioscience-details-consumer-class-actions-thorne-suit-elysium/) Niagen and its ChromaDex subsidiary are sued in two consumer class actions and a Thorne patent case. A Federal Circuit ruling on a $9.2 million fee award to Elysium is pending. [NAGE](https://aibio.space/companies/niagen-bioscience/)
111. Legal · 2026-08-04 [Arrowhead still defending Ionis patent suit over plozasiran after Delaware case was dismissed](https://aibio.space/news/arrowhead-still-defending-ionis-patent-suit-plozasiran-after-delaware/) Ionis sued Arrowhead in California on Sept. 11, 2025 over the '333 patent. Arrowhead, the only named defendant, disputes the claim; its Delaware declaratory action was dismissed Dec. 23, 2025. [ARWR](https://aibio.space/companies/arrowhead-pharmaceuticals/)
112. Legal · 2026-08-04 [OnKure says plaintiffs have not pursued two New York suits over its Reneo merger proxy](https://aibio.space/news/onkure-says-plaintiffs-have-not-pursued-two-new-york-suits-reneo/) Thomas and Kent v. Reneo name Reneo and unnamed individual defendants. The 10-Q says plaintiffs have not pursued the claims; the 2024 proxy lists Reneo's board. [OKUR](https://aibio.space/companies/onkure-therapeutics/)
113. Legal · 2026-08-03 [Krystal Biotech reports DOJ subpoenas on VYJUVEK testing program, director pay suit settlement](https://aibio.space/news/krystal-biotech-reports-doj-subpoenas-vyjuvek-testing-program-director/) The company and certain employees received Justice Department subpoenas in early 2025. A Delaware derivative suit over non-employee director pay has a fairness hearing set for September 14, 2026. [KRYS](https://aibio.space/companies/krystal-biotech/)
114. Legal · 2026-08-03 [Krystal Biotech sued in Delaware over inventorship of two KB407 cystic fibrosis patents](https://aibio.space/news/krystal-biotech-sued-delaware-inventorship-two-kb407-cystic-fibrosis/) Jonathan Forman says he conceived of inventions claimed in two U.S. patents and was wrongly left off as an inventor. Krystal is the named defendant and says the claims are without merit. [KRYS](https://aibio.space/companies/krystal-biotech/)
115. Legal · 2026-08-03 [Supernus faces January 2027 APOKYN antitrust trial; related insurance suits pending](https://aibio.space/news/supernus-faces-january-2027-apokyn-antitrust-trial-related-insurance/) Sage Chemical and TruPharma sued Supernus, Britannia, US WorldMeds and others in Delaware. Four individuals were dismissed in 2024. Insurance coverage suits tied to an unnamed Delaware action are open. [SUPN](https://aibio.space/companies/supernus-pharmaceuticals/)
116. Legal · 2026-08-03 [Ocular Therapeutix faces EyePoint defamation suit; injunction ruling still pending](https://aibio.space/news/ocular-therapeutix-faces-eyepoint-defamation-suit-injunction-ruling/) EyePoint, Inc. sued Ocular in Massachusetts state court on March 20, 2026 over alleged false statements about DURAVYU. The court denied a restraining order on April 13 and has not ruled on a preliminary injunction. [OCUL](https://aibio.space/companies/ocular-therapeutix/)
117. Legal · 2026-07-31 [Organon faces securities class action over dividend statements and a merger proxy suit](https://aibio.space/news/organon-faces-securities-class-action-dividend-statements-merger-proxy/) Teamsters Local 710 leads a consolidated New Jersey class action against Organon and unnamed officers. Two derivative suits are stayed, and a July 6 suit against the board and Sun Pharma entities challenges the merger proxy. [OGN](https://aibio.space/companies/organon/)
118. Legal · 2026-07-30 [Bristol Myers Squibb details Texas Plavix suit, Arkansas 340B complaint and Celgene settlement](https://aibio.space/news/bristol-myers-squibb-details-texas-plavix-suit-arkansas-340b-complaint/) Bristol Myers Squibb's 10-Q says the company and certain Sanofi entities are defendants in a Texas state suit over Plavix labeling, sales and promotion. Arkansas has sued BMS over 340B contract pharmacy policies, and a Celgene securities class action settled with final approval in May 2026. [BMY](https://aibio.space/companies/bristol-myers-squibb/)
119. Legal · 2026-07-30 [Bristol Myers Squibb sues seven generic drugmakers in Delaware over Camzyos patents](https://aibio.space/news/bristol-myers-squibb-sues-seven-generic-drugmakers-delaware-camzyos/) Bristol Myers Squibb's 10-Q says it sued seven generic drugmakers in the U.S. District Court for the District of Delaware over Camzyos patents. The defendants are Aurobindo, Zenara, Micro Labs, Dr. Reddy's, Annora, Apotex and MSN. The filing gives no case numbers, filing dates or rulings. [BMY](https://aibio.space/companies/bristol-myers-squibb/)
120. Legal · 2026-07-30 [Baxter faces two securities class actions and a derivative suit over Novum LVP statements](https://aibio.space/news/baxter-faces-two-securities-class-actions-derivative-suit-novum-lvp/) Suits in Illinois federal court allege misleading statements about Baxter's Novum LVP pump. The 10-Q names Baxter and unnamed officers; the derivative captions name Jose E. Almeida. [BAX](https://aibio.space/companies/baxter-international/)
121. Legal · 2026-07-30 [Baxter's Hillrom unit faces Linet antitrust suit, a bed-buyer appeal and two DOJ requests](https://aibio.space/news/baxters-hillrom-unit-faces-linet-antitrust-suit-bed-buyer-appeal-two/) Linet Americas sued Hill-Rom Holdings, Hill-Rom Company and Hill-Rom Services in 2021. A dismissed class action is on appeal, and a DOJ demand and subpoena remain open. [BAX](https://aibio.space/companies/baxter-international/)
122. Legal · 2026-07-28 [Alkermes sues Teva, Apotex and MSN over proposed generic Lybalvi](https://aibio.space/news/alkermes-sues-teva-apotex-msn-proposed-generic-lybalvi/) Two Alkermes subsidiaries filed Hatch-Waxman patent suits in New Jersey and Delaware against Teva Pharmaceuticals, Apotex and MSN entities. FDA approval of each generic application is stayed for up to 30 months. [ALKS](https://aibio.space/companies/alkermes/)
123. Legal · 2026-07-28 [Alkermes faces direct-purchaser antitrust class action over Vivitrol patent](https://aibio.space/news/alkermes-faces-direct-purchaser-antitrust-class-action-vivitrol-patent/) Value Drug Company sued Alkermes, Inc. and Alkermes Pharma Ireland Limited in Massachusetts in October 2025. A December 2025 motion to dismiss is the latest step the 10-Q reports. [ALKS](https://aibio.space/companies/alkermes/)
124. Legal · 2026-07-23 [Summit Therapeutics derivative suit over $520 million Duggan notes ends in voluntary dismissal](https://aibio.space/news/summit-therapeutics-derivative-suit-520-million-duggan-notes-ends/) Rainaldi Revocable Trust sued certain current and former Summit directors in Delaware Chancery in 2025, with Summit a nominal defendant. The parties stipulated to dismissal on May 27, 2026. [SMMT](https://aibio.space/companies/summit-therapeutics/)
125. Legal · 2026-07-08 [Evommune CFO agrees to return $10,160 short-swing profit after July share purchase](https://aibio.space/news/evommune-cfo-agrees-return-10-160-short-swing-profit-after-july-share/) Evommune's chief financial officer disclosed a purchase that matches a May sale under the short-swing rule, and agreed to pay the company $10,160. [EVMN](https://aibio.space/companies/evommune/)
126. Legal · 2026-06-22 [Former SPAC sponsor sues Silexion in Tel Aviv over note conversions](https://aibio.space/news/former-spac-sponsor-sues-silexion-tel-aviv-note-conversions/) Defendants: Silexion, chairman and CEO Ilan Hadar, and CFO Mirit Horenshtein Hadar. Moringa Sponsor disputes how Silexion converted part of a $3,433 thousand note into shares and alternatively demands cash; Silexion says it complied with the note. [SLXN](https://aibio.space/companies/silexion-therapeutics/)
127. Legal · 2026-06-02 [Delaware court holds Heron CINVANTI patent claims invalid; Heron plans appeal](https://aibio.space/news/delaware-court-holds-heron-cinvanti-patent-claims-invalid-heron-plans/) The court ruled June 1, 2026 in Heron's patent suit against Azurity Pharmaceuticals and Slayback Pharma entities. Heron says it will appeal to the Federal Circuit and that the ruling does not affect a prior settlement. [HRTX](https://aibio.space/companies/heron-therapeutics/)
128. Legal · 2026-05-29 [Cardiff Oncology disputes Nerviano's termination of 2017 license agreement](https://aibio.space/news/cardiff-oncology-disputes-nervianos-termination-2017-license-agreement/) Nerviano Medical Sciences told Cardiff on May 27, 2026 it was ending the License Agreement over a patent inventorship dispute. Cardiff, which sued NMS as defendant on May 19, says the notice is legally ineffective. [CRDF](https://aibio.space/companies/cardiff-oncology/)
129. Legal · 2026-05-22 [SpyGlass countersues Glaukos in trade-secret case; trial moved to January 2027](https://aibio.space/news/spyglass-countersues-glaukos-trade-secret-case-trial-moved-january/) Defendants are SpyGlass Pharma and employee Long Doan. SpyGlass countersued Glaukos on May 22 over contract interference, and the court moved trial to January 2027. [SGP](https://aibio.space/companies/spyglass-pharma/)[GKOS](https://aibio.space/companies/glaukos/)
130. Legal · 2026-05-07 [Capricor sues Nippon Shinyaku and NS Pharma over Deramiocel U.S. distribution agreement](https://aibio.space/news/capricor-sues-nippon-shinyaku-ns-pharma-deramiocel-u-s-distribution/) Capricor Therapeutics filed a complaint in New Jersey seeking to rescind its January 24, 2022 distribution agreement and asking for a preliminary injunction. The FDA target action date for Deramiocel is August 22, 2026. [CAPR](https://aibio.space/companies/capricor-therapeutics/)
131. Legal · 2026-03-16 [Fennec Pharmaceuticals settles PEDMARK patent litigation with Cipla](https://aibio.space/news/fennec-pharmaceuticals-settles-pedmark-patent-litigation-cipla/) Under a license agreement, the lawsuit will be dismissed and Cipla will not sell a generic version in the U.S. until September 1, 2033, or earlier under specified circumstances. Each side bears its own costs. [FENC](https://aibio.space/companies/fennec-pharmaceuticals/)
132. Legal · 2026-03-03 [Arbutus and Genevant settle Moderna LNP patent litigation, $950.0 million due by July 8, 2026](https://aibio.space/news/arbutus-genevant-settle-moderna-lnp-patent-litigation-950-0-million/) Moderna agrees to pay a $950.0 million noncontingent lump sum and may owe a further $1.3 billion depending on a Federal Circuit appeal on 28 U.S.C. §1498. Arbutus is entitled to 20% of proceeds after litigation costs, or, if less, tiered low single-digit royalties. [ABUS](https://aibio.space/companies/arbutus-biopharma/)
133. Legal · 2025-12-31 [Climb Bio sues Alumis and Acelyrin over $3 million budoprutug milestone payment](https://aibio.space/news/climb-bio-sues-alumis-acelyrin-3-million-budoprutug-milestone-payment/) Climb Bio filed a complaint in Delaware Superior Court against Alumis Inc. and Acelyrin, Inc. It asks for a declaration that budoprutug is not a Product under a 2024 asset purchase agreement, and that Climb does not owe a $3 million milestone payment. [CLYM](https://aibio.space/companies/climb-bio/)
134. Legal · 2025-12-23 [Cassava Sciences (now Filana Therapeutics) agrees to $31.25 million class action settlement](https://aibio.space/news/cassava-sciences-now-filana-therapeutics-agrees-31-25-million-class/) Cassava and Chief Financial Officer Eric J. Schoen accepted a mediator's recommendation to settle the consolidated securities class action for $31.25 million. Remi Barbier and Lindsay Burns did not sign the term sheet but would receive releases once the court approves. [FLNA](https://aibio.space/companies/filana-therapeutics/)
135. Legal · 2025-11-21 [AnaptysBio sues Tesaro and GSK in Delaware Chancery Court over Jemperli collaboration](https://aibio.space/news/anaptysbio-sues-tesaro-gsk-delaware-chancery-court-jemperli/) AnaptysBio's Verified Complaint of Nov 20, 2025 names Tesaro, Inc. and its parent GlaxoSmithKline and alleges breaches of the Jemperli collaboration. Tesaro sued AnaptysBio the same day, and the parties have agreed to ask for an expedited schedule. [ANAB](https://aibio.space/companies/anaptysbio/)
136. Legal · 2025-10-14 [Allogene discloses Factor Bioscience patent suit against licensor Cellectis; it is not a party](https://aibio.space/news/allogene-discloses-factor-bioscience-patent-suit-against-licensor/) Factor Bioscience sued Cellectis and AstraZeneca in Delaware federal court on Sept 26, 2025, over TALEN gene-editing technology. Allogene is not a party, but it licenses that technology from Cellectis and says Factor may still sue it directly. [ALLO](https://aibio.space/companies/allogene-therapeutics/)
137. Legal · 2025-08-20 [Enanta files patent infringement suit against Pfizer over Paxlovid in EU Unified Patent Court](https://aibio.space/news/enanta-files-patent-infringement-suit-against-pfizer-paxlovid-eu/) Enanta Pharmaceuticals says it sued Pfizer Inc. and certain of its subsidiaries in the Unified Patent Court on Aug 20, 2025, alleging infringement of a European patent through Paxlovid sales. The claim is untested, and no hearing date is given. [ENTA](https://aibio.space/companies/enanta-pharmaceuticals/)
138. Legal · 2025-08-18 [Unicycive discloses securities class action over oxylanthanum carbonate statements](https://aibio.space/news/unicycive-discloses-securities-class-action-oxylanthanum-carbonate/) Unicycive said a securities class action was filed in the Northern District of California against the company and certain of its officers, who are not named. The suit concerns statements about its oxylanthanum carbonate application. The company calls the claims meritless. [UNCY](https://aibio.space/companies/unicycive-therapeutics/)
139. Legal · 2025-08-08 [ImmunityBio gets preliminary court approval of shareholder derivative lawsuit settlement](https://aibio.space/news/immunitybio-gets-preliminary-court-approval-shareholder-derivative/) A federal court preliminarily approved the settlement of three shareholder derivative suits naming ImmunityBio's current and former officers and directors. The company agrees to governance reforms and expects its insurer to pay the plaintiffs' attorneys' fees, which their counsel plans to ask the court to set at up to $1,400,000. The final hearing is November 4, 2025. [IBRX](https://aibio.space/companies/immunitybio/)
140. Legal · 2025-08-01 [Protalix says Delaware stockholder class action over bylaws is dismissed, $160,000 in counsel fees](https://aibio.space/news/protalix-says-delaware-stockholder-class-action-bylaws-dismissed-160/) A Delaware stockholder class action against Protalix BioTherapeutics and its board, Thomas v. Bashan, et al., was dismissed as to the plaintiff after the board amended the bylaws. Protalix agreed to pay $160,000 in fees and expenses to the plaintiff's counsel, and it denies the allegations. [PLX](https://aibio.space/companies/protalix-biotherapeutics-de/)
141. Legal · 2025-06-26 [Cell Source auditor Marcum resigns after CBIZ takes over its attest business](https://aibio.space/news/cell-source-auditor-marcum-resigns-after-cbiz-takes-attest-business/) Marcum LLP resigned as Cell Source's auditor on June 26, 2025, after CBIZ CPAs took over its attest practice. Marcum's reports on 2022 and 2023 carried a going-concern paragraph. [CLCS](https://aibio.space/companies/cell-source/)
142. Legal · 2025-06-05 [Harmony Biosciences settles WAKIX patent suit with Lupin, generic entry set for 2030](https://aibio.space/news/harmony-biosciences-settles-wakix-patent-suit-lupin-generic-entry-set/) Lupin Limited gets a license to launch a generic WAKIX no earlier than January 2030, or July 2030 with pediatric exclusivity, and the Delaware case will be dismissed. [HRMY](https://aibio.space/companies/harmony-biosciences/)
143. Legal · 2025-05-29 [Taysha Gene Therapies prices public offering of 46,868,687 shares and pre-funded warrants at $2.75](https://aibio.space/news/taysha-gene-therapies-prices-public-offering-46-868-687-shares-pre/) Taysha Gene Therapies agreed to sell 46,868,687 shares and pre-funded warrants for 25,858,586 more at $2.75 a share, with net proceeds estimated at $187.4 million. The company says that money and its existing cash will last into 2028, and the filing names no lawsuit or defendant. [TSHA](https://aibio.space/companies/taysha-gene-therapies/)
144. Legal · 2025-05-23 [Emergent BioSolutions derivative lawsuit settlement gets preliminary court approval](https://aibio.space/news/emergent-biosolutions-derivative-lawsuit-settlement-gets-preliminary/) The U.S. District Court for the District of Maryland granted preliminary approval on May 9, 2025 to a settlement of shareholder derivative suits against current and former Emergent directors and officers. The settlement provides a $15 million payment to the company from insurance and governance reforms, and final approval is set for August 6, 2025. [EBS](https://aibio.space/companies/emergent-biosolutions/)
145. Legal · 2025-05-20 [Acadia Pharmaceuticals wins Delaware ruling on NUPLAZID formulation patent](https://aibio.space/news/acadia-pharmaceuticals-wins-delaware-ruling-nuplazid-formulation/) A federal court in Delaware ruled for Acadia on infringement and validity of the '721 patent against Aurobindo and MSN entities. The company also signed a lease of 12 years and two months for new Princeton offices. [ACAD](https://aibio.space/companies/acadia-pharmaceuticals/)
146. Legal · 2025-05-12 [United Therapeutics files patent infringement suit against Liquidia over YUTREPIA](https://aibio.space/news/united-therapeutics-files-patent-infringement-suit-against-liquidia/) The complaint alleges Liquidia infringes U.S. Patent No. 11,357,782 and seeks to bar Liquidia from commercializing YUTREPIA if approved. Liquidia says the claims mirror a patent that the Patent Trial and Appeal Board held invalid. [LQDA](https://aibio.space/companies/liquidia/)
147. Legal · 2025-04-03 [Arbutus says court moved Moderna patent trial to September 29, 2025](https://aibio.space/news/arbutus-says-court-moved-moderna-patent-trial-september-29-2025/) Arbutus Biopharma and Genevant Sciences sued Moderna, Inc. and a Moderna affiliate, which the filing does not name, over patents tied to the MRNA-1273 COVID-19 vaccine. On March 31, 2025 the court moved the patent trial from September 24 to September 29, 2025. [ABUS](https://aibio.space/companies/arbutus-biopharma/)
148. Legal · 2025-02-28 [Court denies Liquidia's challenge to FDA exclusivity for Tyvaso DPI](https://aibio.space/news/court-denies-liquidias-challenge-fda-exclusivity-tyvaso-dpi/) A federal judge in Washington denied Liquidia's summary judgment motion on February 27, 2025, upholding the FDA's three-year exclusivity for United Therapeutics' Tyvaso DPI. The exclusivity still ends May 23, 2025, and a related cross claim remains pending. [LQDA](https://aibio.space/companies/liquidia/)

---
Source page: https://aibio.space/legal/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Biotech lawsuits and securities class actions, latest", 2026-10-31, https://aibio.space/legal/